iHeart Japan is developing allogeneic regenerative medicinal products derived from iPS cells, and selling research tools for cardiotoxicity and efficacy. The base technology was invented by Prof. Jun Yamashita of Kyoto Univ. Center of iPSC Research and Application.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
IHJ-301(iPSC-derived multilayered cardiac cell sheets)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):